Press Releases

GlobeNewswire, Inc.

Q3 2026 product revenue of €366 million (+89% Y/Y), comprising €291 million for YORVIPATH®, €59 million for SKYTROFA®, and €16 million for YUVIWEL® Received positive CHMP and COMP opinions recommending EU marketing authorization and maintenance of...

GlobeNewswire, Inc.

Company announcement – No. 56 / 2026 Zealand Pharma Announces Financial Results for the First Nine Months of 2026 Advancing at pace towards Metabolic Frontier 2030: petrelintide in Phase 3, survodutide moving towards regulatory filings, positive...

DVIDS - Georgia

For Tech. Sgt. Casey Wachowiak, effective medical care begins with trust.

GlobeNewswire, Inc.

COPENHAGEN, Denmark, November 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces its financial calendar for 2027 as summarized...

GlobeNewswire, Inc.

COPENHAGEN, Denmark, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 17, 2026, at...

GlobeNewswire, Inc.

TORONTO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development and manufacturing of MDXX-class molecules, including...

GlobeNewswire, Inc.

Company announcement – No. 55 / 2026 Zealand Pharma announces Boehringer Ingelheim’s survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase 3 SYNCHRONIZE-CVOT trial with...

GlobeNewswire, Inc.

Press release – No. 23 / 2026 Zealand Pharma to participate in the Jefferies Global Healthcare Conference Copenhagen, Denmark, November 9, 2026 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming metabolic...

GlobeNewswire, Inc.

Publication in Nature Communications confirmed TG4050’s robust clinical proof of principle, with 100% DFS sustained after more than 3 years of follow-up in head and neck cancer (HNSCC) Expansion of the myvac® platform with the initiation of the...

GlobeNewswire, Inc.

COM002 is a first-in-class complement-powered immune engager based on Commit Biologics’ proprietary BiCE™ platform.

GlobeNewswire, Inc.

Treatment-related adverse events occurred in 1 of 12 ET-700 participants compared with 8 of 12 GALZIN® participants Hepatic copper uptake decreased 12% with ET-700, compared with a 46% decrease with GALZIN, and an 11% increase with placebo Company...

GlobeNewswire, Inc.

Press Release – No. 22 / 2026 Zealand Pharma conference call on Nov 12 at 2pm CET (8am ET) to present third quarter 2026 financial results Copenhagen, Denmark, November 5, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a...

GlobeNewswire, Inc.

Phase 3 SONATA-HCM study substantially overenrolled; top-line data expected Q1 2027 Positive STENO1 safety data strengthens benefit-risk profile for ZYNQUISTA® NDA resubmission Phase 1 clinical development of LX9851 ongoing by Novo Conference call...

GlobeNewswire, Inc.

AUSTIN, Texas, Nov. 05, 2026 (GLOBE NEWSWIRE) -- ESO Solutions, Inc. (“ESO”), a leading data services and software provider for fire departments, EMS, hospitals, and government agencies, today announced the appointment of three associate chief...

GlobeNewswire, Inc.

Company Announcement COPENHAGEN, Denmark; November 11, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the...

EIN Presswire

Exploring Industry Developments, Material Technologies, and Manufacturing Capabilities in China's Zero Silica Sector CALIFORNIA, CA, UNITED STATES, November 12, 2026 /⁨EINPresswire.com⁩/ -- Industry Context: The Growing Demand for Zero Silica...

GlobeNewswire, Inc.

First clinical data for sutacimig in Factor VII deficiency (FVIID) shows multi-fold accumulation of endogenous FVII(a) with shortening of prothrombin time after a single subcutaneous dose in initial participants of the Phase 2b study Preclinical...

GlobeNewswire, Inc.

Agreement builds on customer’s long-term deal in new Yokohama facility for five commercial biologics programs, now allocating an additional six commercial programs to Copenhagen facility to consolidate high-volume, single-use biologics...

GlobeNewswire, Inc.

This international award, honoring “the best of the best” in medical innovation, represents yet another important external recognition of AI-Immunology™ COPENHAGEN, Denmark, October 30, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a...

GlobeNewswire, Inc.

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life...